Last reviewed · How we verify

Olanzapine-samidorphan + exercise

New York State Psychiatric Institute · FDA-approved active Small molecule

Olanzapine-samidorphan combines an atypical antipsychotic (olanzapine) with a mu-opioid receptor antagonist (samidorphan) to treat schizophrenia and bipolar disorder while mitigating weight gain, with exercise as a behavioral intervention.

Olanzapine-samidorphan combines an atypical antipsychotic with a mu-opioid receptor antagonist to reduce antipsychotic-induced weight gain while maintaining psychiatric symptom control. Used for Schizophrenia with weight gain risk, Bipolar disorder with weight gain risk.

At a glance

Generic nameOlanzapine-samidorphan + exercise
SponsorNew York State Psychiatric Institute
Drug classAtypical antipsychotic with opioid antagonist
TargetDopamine receptors, serotonin receptors (olanzapine); mu-opioid receptor (samidorphan)
ModalitySmall molecule
Therapeutic areaPsychiatry
PhaseFDA-approved

Mechanism of action

Olanzapine acts as a dopamine and serotonin antagonist to manage psychotic symptoms, but commonly causes weight gain and metabolic dysfunction. Samidorphan is a mu-opioid receptor antagonist that blocks opioid-mediated appetite stimulation and metabolic effects, reducing olanzapine-induced weight gain. Exercise serves as an additional non-pharmacological intervention to further improve metabolic outcomes and overall health.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: